This subtle relationship suggests that lexibulin, in particular, might be more suitable for patients with lower SUCLG2 levels and present a therapeutic avenue that could potentially protect patients from unnecessary toxicity while targeting the tumor more effectively. The gene discussed is SUCLG2; the disease is neoplasm.